Zentalis Pharmaceuticals, Inc.

Based in New York, US, and founded in 2014, Zentalis Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company and has operations in both New York and San Diego. Anthony Sun is the Chairman and CEO of the company as of 2021. In 2019, Zentalis Pharmaceuticals, LLC raised USD 85 million in series C funding co-led by new investors and returning investors.

The company raised a total of two funding rounds and became a public company in April 2020. In 2021, Zentalis granted its majority-owned joint venture licenses for ZN-c5, ZN-c3, and ZN-d5. The company is listed on Nasdaq under the ticker symbol "ZNTL. " The company is involved in discovering and developing small-molecule therapeutics targeting fundamental biological pathways of cancers.

It uses an Integrated Discovery Engine, or drug discovery engine, to find targets and produce small-molecule novel chemical entities, or NCEs, with characteristics that it believes might result in potentially distinct product profiles. Zentalis’s pipeline includes two lead product candidates: ZN-c5, which is being developed for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer, and ZN-c3, which is being developed for the treatment of advanced solid tumors as monotherapy and ovarian cancer.